Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Signs $165 Million Deal for China Rights to Bio-Thera's Avastin Biosimilar

publication date: Aug 25, 2020

Beijing's BeiGene acquired China rights to Bio-Thera's Avastin® (bevacizumab) biosimilar in an agreement worth up to $165 million. BeiGene will have the right to develop, manufacture and commercialize BAT1706 in greater China in return for upfront and milestone payments, plus royalties. China's NMPA recently accepted Bio-Thera's BLA filing for review of the biosimilar. Roche's Avastin is approved in China for non-small cell lung cancer and colorectal cancer. Bio-Thera is located in Guangzhou. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.